TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6122461

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 5
Study: 30802271

Group type: EXPERIMENTAL
Intervention: Pre-conception lifestyle intervention (n = 84)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Prompt infertility treatment (Control group, n = 94)
Number of subjects: 178
Study: 28917215

Group type: EXPERIMENTAL
Intervention: Body Project M (intervention)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 74
Study: 25879244

Group type: EXPERIMENTAL
Intervention: Auditory electrical stimulation (AES)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo electrical stimulation (PES)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Residual Inhibition (RI) group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nonresidual Inhibition (NRI) group
Number of subjects: 28
Study: 24325609

Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 22291112

Group type: EXPERIMENTAL
Intervention: Oral cefixime for 10 days
Number of subjects: 171

Group type: COMPARATOR
Intervention: Sequential intravenous ceftriaxone for 4 days followed by oral cefixime for 6 days
Number of subjects: 171
Study: 19468040

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived barriers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity measurement
Number of subjects: 0
Study: 17484939

Group type: EXPERIMENTAL
Intervention: Socioculturally tailored collaborative care intervention
Number of subjects: 446

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 446
Study: 15821197

Group type: EXPERIMENTAL
Intervention: AM3 (3 g/d for 180 days)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 12688144

Group type: EXPERIMENTAL
Intervention: LNGB with cuff fixation (n1-GB+C)
Number of subjects: 691

Group type: COMPARATOR
Intervention: LNGB without cuff fixation (n2-GB-C)
Number of subjects: 691
Study: 9655770

Group type: EXPERIMENTAL
Intervention: LBPP at 25 mmHg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LBPP at 50 mmHg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LBPP at 75 mmHg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LBPP at 25 mmHg during exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LBPP at 50 mmHg during exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LBPP at 75 mmHg during exercise
Number of subjects: 8
Study: 7654486

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg twice daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 2653765

Group type: EXPERIMENTAL
Intervention: Captopril + hydrochlorothiazide (HCT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Digoxin + hydrochlorothiazide (HCT)
Number of subjects: 116
Study: 388401

Group type: EXPERIMENTAL
Intervention: tienilic acid (mean dose 210 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: cyclopenthiazide (as control)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: tienilic acid (mean daily dose of 184 mg)
Number of subjects: 38
Study: 31947040

Group type: EXPERIMENTAL
Intervention: 1-Hz repetitive Transcranial Magnetic Stimulation (rTMS) four times a week for 3 weeks, 20 minutes per session
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1-Hz repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 4
Study: 28785906

Group type: EXPERIMENTAL
Intervention: 3D titanium miniplate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Locking plate
Number of subjects: 40
Study: 25229268

Group type: EXPERIMENTAL
Intervention: Influenza A(H1N1)pnd09 vaccination during pregnancy
Number of subjects: 488

Group type: COMPARATOR
Intervention: Influenza A(H1N1)pnd09 vaccination after pregnancy
Number of subjects: 488
Study: 22856533

Group type: EXPERIMENTAL
Intervention: Meat supplementation
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Milk supplementation
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Plain traditional vegetable stew (githeri)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Control group (no snack)
Number of subjects: 910
Study: 21118395

Group type: EXPERIMENTAL
Intervention: Omeprazole (10 mg once daily) plus mosapride citrate (5 mg three times a day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Omeprazole plus placebo
Number of subjects: 200
Study: 20031745

Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of supersaturated oxygen (SSO(2)) for 90 minutes
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: SSO(2)
Number of subjects: 301
Study: 19391529

Group type: EXPERIMENTAL
Intervention: Auricular point taping and pressing therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Nimodipine (30 mg, thrice daily)
Number of subjects: 180
Study: 15844061

Group type: EXPERIMENTAL
Intervention: Postoperative temperature measurement > or = 38.0 degrees C
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Postoperative temperature measurement < 38 degrees C
Number of subjects: 284
Study: 12383535

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg) orally every hour for a maximum of three doses
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo orally every hour for a maximum of three doses
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 9819040

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at 70 microg/kg dosage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at 35 microg/kg dosage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) in home treatment study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) in compassionate use study
Number of subjects: 0
Study: 7699549

Group type: EXPERIMENTAL
Intervention: Three doses of nebulized ipratropium bromide (250 micrograms/dose)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: One dose of nebulized ipratropium bromide
Number of subjects: 120

Group type: COMPARATOR
Intervention: No ipratropium (Control Group)
Number of subjects: 120
Study: 2539929

Group type: EXPERIMENTAL
Intervention: Eicosapentanoic acid (EPA) 10 g per day
Number of subjects: 37

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 37
Study: 899864

Group type: EXPERIMENTAL
Intervention: Ultrasound method for detection of DVT
Number of subjects: 47

Group type: COMPARATOR
Intervention: Clinical evaluation
Number of subjects: 47
Study: 11770273

Group type: EXPERIMENTAL
Intervention: ThinPrep fluid-based cytology
Number of subjects: 5428
Study: 28658076

Group type: EXPERIMENTAL
Intervention: 100 m front crawl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 200 m front crawl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 400 m front crawl
Number of subjects: 10
Study: 29976746

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control (no everolimus)
Number of subjects: 339
Study: 27018531

Group type: EXPERIMENTAL
Intervention: Individual PCIT
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Group PCIT
Number of subjects: 81
Study: 25369200

Group type: EXPERIMENTAL
Intervention: 600 µg of misoprostol sublingually
Number of subjects: 1140

Group type: COMPARATOR
Intervention: 10 IU of oxytocin intramuscularly
Number of subjects: 1140
Study: 21953471

Group type: EXPERIMENTAL
Intervention: Ibandronate 100 mg monthly
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg monthly
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Ibandronate (100 mg and 150 mg monthly)
Number of subjects: 698
Study: 21526669

Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DLS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fiberoptic Bronchoscopy (FOB)
Number of subjects: 50
Study: 17589341

Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mini-incision open donor nephrectomy (ODN)
Number of subjects: 50
Study: 16222027

Group type: EXPERIMENTAL
Intervention: Household-based ceramic water filters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no filters)
Number of subjects: 0
Study: 12038644

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) exposure
Number of subjects: 33

Group type: COMPARATOR
Intervention: Exposure in vivo
Number of subjects: 33
Study: 10664928

Group type: EXPERIMENTAL
Intervention: Acrivastine 16 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg and 20 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fexofenadine 120 mg
Number of subjects: 40
Study: 7888428

Group type: EXPERIMENTAL
Intervention: Ademetionin (therapy group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 21
Study: 2203518

Group type: EXPERIMENTAL
Intervention: Complete androgen blockade (addition of a pure antiandrogen to castration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Castration
Number of subjects: 0
Study: 70639

Group type: EXPERIMENTAL
Intervention: High wheat-fibre regimen
Number of subjects: 26

Group type: COMPARATOR
Intervention: Low wheat-fibre regimen
Number of subjects: 26
Study: 31740727

Group type: EXPERIMENTAL
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 46
Study: 29875218

Group type: EXPERIMENTAL
Intervention: Fingolimod (FNG)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Fingolimod (FNG) in treatment-naive patients
Number of subjects: 550

Group type: COMPARATOR
Intervention: Dimethyl fumarate (DMF) in treatment-naive patients
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Fingolimod (FNG) in switchers
Number of subjects: 550

Group type: COMPARATOR
Intervention: Dimethyl fumarate (DMF) in switchers
Number of subjects: 550
Study: 26817510

Group type: EXPERIMENTAL
Intervention: Active video gaming
Number of subjects: 22

Group type: COMPARATOR
Intervention: Seated video gaming
Number of subjects: 22
Study: 24656435

Group type: EXPERIMENTAL
Intervention: Systematic Voiding Programme (SVP)
Number of subjects: 43
Study: 23021113

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (Quick 2.0 and Smart Clip) with superelastic or thermoactive archwires
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control teeth (1.1, 1.3, 1.5)
Number of subjects: 40
Study: 21053384

Group type: EXPERIMENTAL
Intervention: Community-based recruitment
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Specialty-based recruitment
Number of subjects: 189

Group type: COMPARATOR
Intervention: Both recruitment settings
Number of subjects: 189
Study: 17438965

Group type: EXPERIMENTAL
Intervention: Preservation of ICBN
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional dissection (Control)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Preservation of LTV
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (No preservation of LTV)
Number of subjects: 126
Study: 15883121

Group type: EXPERIMENTAL
Intervention: Dual-task training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Single-task training
Number of subjects: 18

Group type: COMPARATOR
Intervention: No-training
Number of subjects: 18
Study: 11852377

Group type: EXPERIMENTAL
Intervention: Glucotrend Premium monitor (Group B)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: One Touch Profile monitor (Group C)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Previous system (Group A)
Number of subjects: 179
Study: 9134079

Group type: EXPERIMENTAL
Intervention: Individual therapy (1 hour per week)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Intensive group therapy (3 hours, 3 times weekly)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Randomly assigned to individual therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Randomly assigned to intensive group therapy
Number of subjects: 67
Study: 7892014

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 45 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 2831814

Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2b interferon at 2.5 x 10(6) IU per day
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2b interferon at 1.7 x 10(6) IU per day
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2b interferon at 3.0 x 10(6) IU per day (previous year)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Once-daily use of interferon
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Lower dose of interferon
Number of subjects: 1200
Study: 31549770

Group type: EXPERIMENTAL
Intervention: Low-dose-rate brachytherapy
Number of subjects: 43000
Study: 30939090

Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Number of subjects: 491

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 491
Study: 29183525

Group type: EXPERIMENTAL
Intervention: Hypotension group (refractory hypotension without hyperlactatemia)
Number of subjects: 1588

Group type: EXPERIMENTAL
Intervention: Hyperlactatemia group (hyperlactatemia without refractory hypotension)
Number of subjects: 1588

Group type: EXPERIMENTAL
Intervention: Typical group (both refractory hypotension and hyperlactatemia)
Number of subjects: 1588

Group type: COMPARATOR
Intervention: Comparison among the three groups
Number of subjects: 1588

Group type: COMPARATOR
Intervention: Comparison between hyperlactatemia group and typical group
Number of subjects: 1588
Study: 25179265

Group type: EXPERIMENTAL
Intervention: Brief sexual risk reduction intervention
Number of subjects: 617

Group type: COMPARATOR
Intervention: Education-only control condition
Number of subjects: 617
Study: 22725836

Group type: EXPERIMENTAL
Intervention: Curcuminoid/piperine treatment (4 g curcuminoids plus 24 mg piperine)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 21631380

Group type: EXPERIMENTAL
Intervention: Weight loss plus exercise program (6-month duration)
Number of subjects: 0
Study: 18155179

Group type: EXPERIMENTAL
Intervention: Response-compatible flanker of a non-target color at varying distances from the target.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response-incompatible flanker of a non-target color at varying distances from the target.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-cued target location and higher salience target than flanker.
Number of subjects: 0
Study: 16407967

Group type: EXPERIMENTAL
Intervention: Mild hypothermia via selective head cooling for 72 hours
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Mild hypothermia via selective head cooling
Number of subjects: 58
Study: 12616587

Group type: EXPERIMENTAL
Intervention: Latino and Native American participants
Number of subjects: 9069

Group type: EXPERIMENTAL
Intervention: Ethnic minority subjects with self‐acknowledged eating and weight concerns
Number of subjects: 9069

Group type: EXPERIMENTAL
Intervention: Ethnic minority subjects
Number of subjects: 9069
Study: 10849033

Group type: EXPERIMENTAL
Intervention: Group 1 (migraine for 2 years or less)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Group 2 (migraine for 10 years or more)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (17 healthy subjects)
Number of subjects: 49
Study: 9407253

Group type: EXPERIMENTAL
Intervention: Carbohydrate drinks (CHO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo drinks (P)
Number of subjects: 16
Study: 7957538

Group type: EXPERIMENTAL
Intervention: 20 mg fosinopril daily for 16 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 4 weeks followed by 50 mg atenolol daily for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo wash-out period of 2-6 weeks prior to treatment
Number of subjects: 50
Study: 2954969

Group type: EXPERIMENTAL
Intervention: Golytely (with bisacodyl)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 107
Study: 29288309

Group type: EXPERIMENTAL
Intervention: Nefopam (0.2 mg/kg bolus, 120 μg/kg/h continuous infusion)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 58
Study: 26705744

Group type: EXPERIMENTAL
Intervention: Positive training program
Number of subjects: 86

Group type: COMPARATOR
Intervention: Comparison training program
Number of subjects: 86
Study: 25017612

Group type: EXPERIMENTAL
Intervention: Everolimus + Exemestane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + Exemestane
Number of subjects: 0
Study: 22248223

Group type: EXPERIMENTAL
Intervention: 0.5% clarithromycin gel (CLM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 61
Study: 20957329

Group type: EXPERIMENTAL
Intervention: Psychological treatment (problem-solving)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18275619

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MUFA-rich)
Number of subjects: 20
Study: 16864148

Group type: EXPERIMENTAL
Intervention: E2/NETA (2 mg E2 plus 1 mg NETA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 9562935

Group type: EXPERIMENTAL
Intervention: Thrombolysis or primary coronary angioplasty
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Resting left ventricular ejection fraction
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Exercise testing eligibility
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Risk score from exercise test variables
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Radionuclide ventriculography
Number of subjects: 272
Study: 7650224

Group type: EXPERIMENTAL
Intervention: 40-mg famotidine wafer
Number of subjects: 450

Group type: COMPARATOR
Intervention: 20-mg and 40-mg famotidine wafers
Number of subjects: 450
Study: 2468734

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (8 mg/kg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 137410

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 11
Study: 6972294

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2, 0.5 mg administered 15 min before aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin, 600 mg four times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2, 0.5 mg four times daily
Number of subjects: 0
Study: 30784641

Group type: EXPERIMENTAL
Intervention: Major stroke
Number of subjects: 3763

Group type: EXPERIMENTAL
Intervention: Stage 3 acute kidney injury
Number of subjects: 3763

Group type: EXPERIMENTAL
Intervention: Moderate or severe paravalvular leak (PVL)
Number of subjects: 3763

Group type: EXPERIMENTAL
Intervention: Life-threatening bleeding
Number of subjects: 3763

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 3763

Group type: EXPERIMENTAL
Intervention: Mild paravalvular leak (PVL)
Number of subjects: 3763

Group type: EXPERIMENTAL
Intervention: New pacemaker implantation
Number of subjects: 3763

Group type: EXPERIMENTAL
Intervention: Minor stroke
Number of subjects: 3763

Group type: EXPERIMENTAL
Intervention: Vascular injury
Number of subjects: 3763
Study: 29371008

Group type: EXPERIMENTAL
Intervention: School-based program promoting outdoor activities (up to 11 hours weekly)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: School-based program promoting outdoor activities (≥200 minutes outdoors)
Number of subjects: 693
Study: 26507428

Group type: EXPERIMENTAL
Intervention: Polyhexanide
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Polyhexanide (PP analysis)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo (PP analysis)
Number of subjects: 146
Study: 24618499

Group type: EXPERIMENTAL
Intervention: Intratympanic Dexamethasone (ITD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 26
Study: 22020318

Group type: EXPERIMENTAL
Intervention: Vorinostat 800 mg/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Vorinostat 1400 mg/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: 5-FU/LV (combined with vorinostat)
Number of subjects: 43
Study: 19194050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 2.5 microg exenatide
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 5 microg exenatide
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 10 microg exenatide
Number of subjects: 153
Study: 16712781

Group type: EXPERIMENTAL
Intervention: schema focused therapy or transference focused psychotherapy
Number of subjects: 50
Study: 15238062

Group type: EXPERIMENTAL
Intervention: Alcohol (0.82 g/kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 11956511

Group type: EXPERIMENTAL
Intervention: Indinavir (C(max) > 7 microg/ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indinavir (C(max) < 7 microg/ml)
Number of subjects: 20
Study: 9822864

Group type: EXPERIMENTAL
Intervention: Greater than normal expression of platelet P-selectin (33.7 +/- 1.1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Greater than normal expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) (57.1 +/- 2.3)
Number of subjects: 23
Study: 7917442

Group type: COMPARATOR
Intervention: Daily alcohol consumption
Number of subjects: 17824
Study: 2816584

Group type: EXPERIMENTAL
Intervention: YAG-laser irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: TUR (Transurethral Resection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0